Premium
Deferiprone‐associated myelotoxicity
Author(s) -
AlRefaie F. N.,
Wonke B.,
Hoffbrand A. V.
Publication year - 1994
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1994.tb01323.x
Subject(s) - deferiprone , neutropenia , medicine , incidence (geometry) , clinical trial , pediatrics , absolute neutrophil count , gastroenterology , chemotherapy , thalassemia , physics , optics
Agranulocytosis developed in a 63‐year‐old patient with myelodysplasia 6 weeks after commencing treatment with the oral iron chelator deferiprone (L 1 , 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one, CP20) at a daily dose of 79 mg/kg. This was the 3rd case of agranulocytosis (neutrophils 0 times 10 9 /***1) in clinical trials of L 1 at the Royal Free Hospital. The neutrophil count recovered 7 days after stopping and commencing G‐CSF at a dose of 300 μg daily. Three other patients with milder degrees of neutropenia (neutrophils <1.5 times 10 9 /1) have also been observed in our trials. The case histories of these 4 patients are described here; other reported cases of neutropenia or agranulocytosis are reviewed. Based on worldwide long‐term clinical trials the incidence of agranulocytosis is about 1.6% and of neutropenia 2%.